Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  International Journal of Cardiology

• Publication date

  2013-09-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijcard.2013.01.052PMID 23414744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013cited by this paper
• Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials

  2012cited by this paper
• Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials.

  2012cited by this paper
• Tailored angiogenesis inhibition in cancer therapy: Respecting the heart to improve the net outcome

  2012influential reference
• Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

  2011cited by this paper
• Recurrent myocardial infarction associated with gefitinib therapy

  2011cited by this paper
• Pazopanib

  2011cited by this paper
• Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles

  2011cited by this paper
• Scintigraphic Techniques for Early Detection of Cancer Treatment–Induced Cardiotoxicity

  2011cited by this paper
• IGF-1 and atherothrombosis: relevance to pathophysiology and therapy.

  2011influential reference
• Breast cancer chemotherapy induces the release of cell‐free DNA, a novel procoagulant stimulus

  2011cited by this paper
• Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

  2011cited by this paper
• Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?

  2011cited by this paper
• Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

  2011cited by this paper
• Costs of hospital events in patients with metastatic colorectal cancer

  2011cited by this paper
• Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report

  2011cited by this paper
• Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.

  2011cited by this paper
• Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).

  2011cited by this paper
• Myocardial scintigraphy, echocardiography and proBNP for early detection of myocardial cardiotoxicity in breast cancer patients after chemo-radiotherapy.

  2011cited by this paper
• Peripheral arterial ischemic events in cancer patients

  2011cited by this paper
• Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.

  2011cited by this paper
• The GRACE score's performance in predicting in-hospital and 1-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide

  2011cited by this paper
• Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy.

  2010cited by this paper
• Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma

  2010cited by this paper
• Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.

  2010influential reference
• Metronomic chemotherapy: new rationale for new directions

  2010cited by this paper
• Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

  2010cited by this paper
• Microparticles in cancer.

  2010cited by this paper
• Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

  2010cited by this paper
• Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).

  2010cited by this paper
• FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.

  2010cited by this paper
• Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

  2010cited by this paper
• Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

  2010cited by this paper
• Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation.

  2009cited by this paper
• Thrombosis associated with angiogenesis inhibitors.

  2009cited by this paper
• Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

  2009cited by this paper
• Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

  2009cited by this paper
• Absence of Akt1 Reduces Vascular Smooth Muscle Cell Migration and Survival and Induces Features of Plaque Vulnerability and Cardiac Dysfunction During Atherosclerosis

  2009cited by this paper
• Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

  2009influential reference
• Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

  2009cited by this paper
• Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

  2008cited by this paper
• Plasma membrane microparticles in angiogenesis: role in ischemic diseases and in cancer.

  2008cited by this paper
• Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

  2008cited by this paper
• Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics

  2008cited by this paper
• Vascular complications of selected cancer therapies

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Cardiovascular risk in long‐term survivors of testicular cancer

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Autoimmune-mediated atherothrombosis

  2008cited by this paper
• Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

  2007cited by this paper
• Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

  2007cited by this paper
• Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

  2007cited by this paper
• Annexin A5 as a Novel Player in Prevention of Atherothrombosis in SLE and in the General Population

  2007cited by this paper
• Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

  2007cited by this paper
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?

  2007cited by this paper
• Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

  2007cited by this paper
• Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease.

  2007cited by this paper
• Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes

  2007cited by this paper
• Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

  2006cited by this paper
• Hypoxia-Inducible Factor-1-Dependent and -Independent Regulation of Insulin-Like Growth Factor-1-Stimulated Vascular Endothelial Growth Factor Secretion

  2006cited by this paper
• Comparing antibody and small-molecule therapies for cancer

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006influential reference
• Tyrosine kinases as targets for cancer therapy.

  2005cited by this paper
• The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.

  2005cited by this paper
• The role of endothelial cell apoptosis in inflammatory and immune diseases

  2005cited by this paper
• N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

  2005cited by this paper
• A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.

  2004cited by this paper
• A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry

  2004cited by this paper
• Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy

  2004cited by this paper
• First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.

  2002influential reference
• Clinical management of gastrointestinal stromal tumors: before and after STI-571.

  2002cited by this paper
• Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation

  2001cited by this paper
• 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.

  2000cited by this paper
• Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban

  1999cited by this paper
• Angiographic findings in patients with refractory unstable angina according to troponin T status.

  1999cited by this paper
• Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.

  1999cited by this paper
• Apoptotic vascular endothelial cells become procoagulant.

  1997cited by this paper
• Apoptotic vascular endothelial cells become procoagulant

  1997cited by this paper
• Inhibition of insulin‐dependent lipogenesis and anti‐lipolysis by protein tyrosine kinase inhibitors.

  1989cited by this paper

• The effects of acetylated cordycepin derivatives on promoting vascular angiogenesis and attenuating myocardial ischemic injury

  2024cites this paper
• When Two Maladies Meet: Disease Burden and Pathophysiology of Stroke in Cancer

  2022cites this paper
• Impact of COVID-19 Pandemic on Surgical Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Multicentric Study

  2021cites this paper
• Myocardial Infarction after Long-Term Treatment with a Tyrosine Kinase Inhibitor (TKI) with Anti-VEGF Receptor Activity

  2019cites this paper
• Arterial hypertension in cancer: The elephant in the room.

  2019cites this paper
• Cardiotoxicity with vascular endothelial growth factor inhibitor therapy

  2018cites this paper
• Use of Antihypertensive Drugs in Neoplastic Patients

  2017cites this paper
• Cardiotoxicity: Cardiac Ischemia

  2017cites this paper
• Vascular Complications of Cancer and Cancer Therapy

  2017cites this paper
• Regulator of G-protein signaling 2 (RGS2) in cardiology and oncology.

  2015cites this paper
• Evaluation, prevention and management of cancer therapy-induced cardiotoxicity: a contemporary approach for clinicians

  2015cites this paper
• Regulator of G-protein signaling 6 (RGS6) in cardiology and oncology.

  2015cites this paper
• A massive pericardial effusion in a cancer patient.

  2015cites this paper
• Insights into cardio-oncology: the patient's heavy cancer journey among doubts, controversies and pitfalls. The role of the cardiologist.

  2015cites this paper
• Mitral valve prolapse caused from ruptured mitral chordae tendineae due to an infective endocarditis in cancer patient.

  2015cites this paper
• Cardiotoxicity: cisplatin and long-term cancer survivors.

  2014cites this paper
• M3 muscarinic acetylcholine receptor in cardiology and oncology.

  2014cites this paper
• Contrast-enhancing right atrial thrombus in cancer patient.

  2014cites this paper
• Cardiotoxicity: trastuzumab and cancer survivors.

  2014cites this paper
• ERBB1/EGFR and ERBB2 (HER2/neu)--targeted therapies in cancer and cardiovascular system with cardiovascular drugs.

  2014cites this paper
• Cardiotoxicity: anthracyclines and long term cancer survivors.

  2014cites this paper
• Cardioinhibitory vasovagal syncope in a cancer patient.

  2014cites this paper
• The chance finding of an atrial septal defect in a cancer patient.

  2014cites this paper
• A challenge in cardiology: the oncosurgery.

  2014cites this paper
• Removal of an intracardiac lost port-A catheter utilizing a simple low-cost method.

  2014cites this paper
• An update on cardio-oncology.

  2014influential citation
• HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs.

  2014cites this paper
• Cancer multidrug resistance-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs.

  2014cites this paper
• Growth factors in preeclampsia: a vascular disease model. A failed vasodilation and angiogenic challenge from pregnancy onwards?

  2013cites this paper